ASH News Daily 2017 - Issue 2 - A-28
ADVANCING OUR RESEARCH IN MULTIPLE MYELOMA
As a world leader in multiple myeloma (MM), Celgene is building
a Future Foundation of research
Please
visit booth
# 1005
to learn about
Celgene's Clinical
Trial programs
in MM
bb2121:
bb2121:
Phase 1 study in
MM / NCT02658929
Phase 2 study in
Relapsed/Refractory
MM (RRMM)
ENROLLING
ENROLLING
SOON
Investigational
agents and/or uses
in clinical development:
CC-92480 +
Dexamethasone:
* BCMA CAR-T: bb2121
* Cereblon Targeting:
Phase 1 study in
RRMM
CC-92480, CC-220,
CC-122
ENROLLING
SOON
* IMiD® Agent:
Pomalidomide
CC-220:
Phase 1/2 study in
RRMM / NCT02773030
ENROLLING
CC-122:
Pomalidomide +
Daratumumab
(MM-014):
Phase 1 study in MM,
NHL, or advanced solid
tumors / NCT01421524
Phase 2 study in
RRMM / NCT01946477
ENROLLING
ENROLLING
Celgene is committed to supporting a robust, global research program that includes investigator-initiated trials and
Cooperative Groups studies.
Celgene continues to support the ongoing Connect® MM registry, the first and largest prospective observational
registry study for patients with MM.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will
receive health authority approval or become commercially available in any country for the uses being investigated.
© 2017 Celgene Corporation
11/17 US-CELG170311
BCMA, B-cell maturation antigen; CAR-T, chimeric antigen receptor T cells; IMiD®, immunomodulatory; MM, multiple myeloma;
NHL, non-Hodgkin lymphoma; RRMM, relapsed/refractory multiple myeloma
Cosmos Communications
1
Q1
Q2
Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 2
ASH News Daily 2017 - Issue 2 - A-1
ASH News Daily 2017 - Issue 2 - A-2
ASH News Daily 2017 - Issue 2 - A-3
ASH News Daily 2017 - Issue 2 - A-4
ASH News Daily 2017 - Issue 2 - A-5
ASH News Daily 2017 - Issue 2 - A-6
ASH News Daily 2017 - Issue 2 - A-7
ASH News Daily 2017 - Issue 2 - A-8
ASH News Daily 2017 - Issue 2 - A-9
ASH News Daily 2017 - Issue 2 - A-10
ASH News Daily 2017 - Issue 2 - A-11
ASH News Daily 2017 - Issue 2 - A-12
ASH News Daily 2017 - Issue 2 - A-13
ASH News Daily 2017 - Issue 2 - A-14
ASH News Daily 2017 - Issue 2 - A-15
ASH News Daily 2017 - Issue 2 - A-16
ASH News Daily 2017 - Issue 2 - A-17
ASH News Daily 2017 - Issue 2 - A-18
ASH News Daily 2017 - Issue 2 - A-19
ASH News Daily 2017 - Issue 2 - A-20
ASH News Daily 2017 - Issue 2 - A-21
ASH News Daily 2017 - Issue 2 - A-22
ASH News Daily 2017 - Issue 2 - A-23
ASH News Daily 2017 - Issue 2 - A-24
ASH News Daily 2017 - Issue 2 - A-25
ASH News Daily 2017 - Issue 2 - A-26
ASH News Daily 2017 - Issue 2 - A-27
ASH News Daily 2017 - Issue 2 - A-28
ASH News Daily 2017 - Issue 2 - B-1
ASH News Daily 2017 - Issue 2 - B-2
ASH News Daily 2017 - Issue 2 - B-3
ASH News Daily 2017 - Issue 2 - B-4
ASH News Daily 2017 - Issue 2 - B-5
ASH News Daily 2017 - Issue 2 - B-6
ASH News Daily 2017 - Issue 2 - B-7
ASH News Daily 2017 - Issue 2 - B-8
ASH News Daily 2017 - Issue 2 - B-9
ASH News Daily 2017 - Issue 2 - B-10
ASH News Daily 2017 - Issue 2 - B-11
ASH News Daily 2017 - Issue 2 - B-12
ASH News Daily 2017 - Issue 2 - B-13
ASH News Daily 2017 - Issue 2 - B-14
ASH News Daily 2017 - Issue 2 - B-15
ASH News Daily 2017 - Issue 2 - B-16
ASH News Daily 2017 - Issue 2 - B-17
ASH News Daily 2017 - Issue 2 - B-18
ASH News Daily 2017 - Issue 2 - B-19
ASH News Daily 2017 - Issue 2 - B-20
ASH News Daily 2017 - Issue 2 - B-21
ASH News Daily 2017 - Issue 2 - B-22
ASH News Daily 2017 - Issue 2 - B-23
ASH News Daily 2017 - Issue 2 - B-24
ASH News Daily 2017 - Issue 2 - B-25
ASH News Daily 2017 - Issue 2 - B-26
ASH News Daily 2017 - Issue 2 - B-27
ASH News Daily 2017 - Issue 2 - B-28
ASH News Daily 2017 - Issue 2 - B-29
ASH News Daily 2017 - Issue 2 - B-30
ASH News Daily 2017 - Issue 2 - B-31
ASH News Daily 2017 - Issue 2 - B-32
ASH News Daily 2017 - Issue 2 - B-33
ASH News Daily 2017 - Issue 2 - B-34
ASH News Daily 2017 - Issue 2 - B-35
ASH News Daily 2017 - Issue 2 - B-36
ASH News Daily 2017 - Issue 2 - B-37
ASH News Daily 2017 - Issue 2 - B-38
ASH News Daily 2017 - Issue 2 - B-39
ASH News Daily 2017 - Issue 2 - B-40
ASH News Daily 2017 - Issue 2 - B-41
ASH News Daily 2017 - Issue 2 - B-42
ASH News Daily 2017 - Issue 2 - B-43
ASH News Daily 2017 - Issue 2 - B-44
ASH News Daily 2017 - Issue 2 - B-45
ASH News Daily 2017 - Issue 2 - B-46
ASH News Daily 2017 - Issue 2 - B-47
ASH News Daily 2017 - Issue 2 - B-48
ASH News Daily 2017 - Issue 2 - B-49
ASH News Daily 2017 - Issue 2 - B-50
ASH News Daily 2017 - Issue 2 - B-51
ASH News Daily 2017 - Issue 2 - B-52
ASH News Daily 2017 - Issue 2 - B-53
ASH News Daily 2017 - Issue 2 - B-54
ASH News Daily 2017 - Issue 2 - B-55
ASH News Daily 2017 - Issue 2 - B-56
ASH News Daily 2017 - Issue 2 - C-1
ASH News Daily 2017 - Issue 2 - C-2
ASH News Daily 2017 - Issue 2 - C-3
ASH News Daily 2017 - Issue 2 - C-4
ASH News Daily 2017 - Issue 2 - C-5
ASH News Daily 2017 - Issue 2 - C-6
ASH News Daily 2017 - Issue 2 - C-7
ASH News Daily 2017 - Issue 2 - C-8
ASH News Daily 2017 - Issue 2 - C-9
ASH News Daily 2017 - Issue 2 - C-10
ASH News Daily 2017 - Issue 2 - C-11
ASH News Daily 2017 - Issue 2 - C-12
ASH News Daily 2017 - Issue 2 - C-13
ASH News Daily 2017 - Issue 2 - C-14
ASH News Daily 2017 - Issue 2 - C-15
ASH News Daily 2017 - Issue 2 - C-16
ASH News Daily 2017 - Issue 2 - C-17
ASH News Daily 2017 - Issue 2 - C-18
ASH News Daily 2017 - Issue 2 - C-19
ASH News Daily 2017 - Issue 2 - C-20
ASH News Daily 2017 - Issue 2 - C-21
ASH News Daily 2017 - Issue 2 - C-22
ASH News Daily 2017 - Issue 2 - C-23
ASH News Daily 2017 - Issue 2 - C-24
ASH News Daily 2017 - Issue 2 - C-25
ASH News Daily 2017 - Issue 2 - C-26
ASH News Daily 2017 - Issue 2 - C-27
ASH News Daily 2017 - Issue 2 - C-28
ASH News Daily 2017 - Issue 2 - C-29
ASH News Daily 2017 - Issue 2 - C-30
ASH News Daily 2017 - Issue 2 - C-31
ASH News Daily 2017 - Issue 2 - C-32
https://www.nxtbookmedia.com